AUA 2025 ARANOTE trial (NCT04736199), ad hoc analysis of the phase III ARANOTE trial, efficacy and safety of darolutamide + ADT in black patients with metastatic hormone-sensitive prostate cancer (mHSPC).
It’s markup week in the House. | It’s markup week in the House for the ‘one big, beautiful bill.’ Lawmakers will debate significant programmatic changes…
This analysis highlights the rapid improvements seen in patients with uncontrolled asthma within 24 hours of their initial rademikibart dose.
Across the country, governors continue to make behavioral health a priority—using their State of the State, budget, and inaugural addresses to highlight investments in behavioral…
Access to diabetes care in lower-income countries still lags for children, despite efforts from insulin makers.
Welcome to Scribe, your new assistant for clinical note-taking! This HIPAA compliant AI-powered tool listens to your patient visits and creates an EHR-ready summary. Say…
Longevity startups have become trendy in digital health, drawing attention from celebrity and established investors.
A joint collection highlighting recent papers that explore the many ways in which the effects of non-coding genetic variation can impact individuals.
The FDA announced it will limit access to Covid-19 vaccines going forward to people 65 and older and others at high risk of serious illness
Oliver Sartor host Ken Herrmann to discuss tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in prostate cancer patients. Dr. Herrmann…
Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk’s Wegovy
